Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thyroid Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    365 result(s) found for: Thyroid Diseases. Displaying page 3 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-002319-25 Sponsor Protocol Number: LOXO-RET-18037 Start Date*: 2019-12-31
    Sponsor Name:LOXO ONCOLOGY INCORPORATED
    Full Title: A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)
    Medical condition: Advanced or metastatic solid tumors with activating Rearranged During Transfection (RET) alterations (and other evidence of RET activation)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001196-20 Sponsor Protocol Number: H2013 Start Date*: 2013-09-24
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO MILANO
    Full Title: PROSPECTIVE STUDY ON THE EFFECTIVENESS OF TWO DIFFERENT DOSES OF INTRAVENOUS METHYLPREDNISOLONE IN THE TREATMENT OF ACUTE DYSTHYROID OPTIC NEUROPATHY
    Medical condition: GRAVES' ORBITOPATHY
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002547-27 Sponsor Protocol Number: OP/CD001 Start Date*: 2005-09-03
    Sponsor Name:University of Bristol
    Full Title: Combined Immunosuppression and Radiotherapy in Thyroid Eye Disease
    Medical condition: Thyroid Eye Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001611-24 Sponsor Protocol Number: CAIN457ADE16 Start Date*: 2021-07-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A two-year multi-center Phase 3 study to investigate the efficacy and safety of secukinumab in adult patients with active, moderate to severe thyroid eye disease (ORBIT), with a randomized, paralle...
    Medical condition: Active, moderate to severe thyroid eye disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10060742 Endocrine ophthalmopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005248-81 Sponsor Protocol Number: INT0111 Start Date*: 2012-01-31
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Differentiated thyroid cancer: metabolic radiotherapy with high activity of radioiodine calculated by individual pre-therapy dosimetry
    Medical condition: Patients bearing differentiated thyroid carcinoma with distant metastases, candidated to metabolic radiotherapy after surgery or repetition of same therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004390-41 Sponsor Protocol Number: BLU-667-1101 Start Date*: 2018-03-13
    Sponsor Name:Blueprint Medicines
    Full Title: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
    Medical condition: Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10066914 Thyroid tumor LLT
    20.0 100000004864 10025044 Lung cancer LLT
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000687-41 Sponsor Protocol Number: LEVOLIO Start Date*: 2016-08-01
    Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DI MODENA
    Full Title: COMBINED SUBSTITUTIVE THERAPY WITH LEVOTHYROXINE AND LIOTHYRONINE IN THYROIDECTOMIZED PATIENTS: EFFECTS ON PERIPHERICAL TISSUES. A PROSPECTIVE RANDOMIZED CONTROLLED DOUBLE BLIND STUDY.
    Medical condition: Post-surgical hypothyroidism in substitutive therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10036429 Postsurgical hypothyroidism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000209-35 Sponsor Protocol Number: 7805 Start Date*: 2016-08-24
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Adjuvant rituximab – a potential treatment for the young patient with Graves’ hyperthyroidism
    Medical condition: Graves' hyperthyroidism
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000123-20 Sponsor Protocol Number: 202200014 Start Date*: 2022-08-16
    Sponsor Name:University Medical Centre Groningen
    Full Title: Prospective, single-centre, feasibility study to evaluate the use of 18F-PSMA PET/CT in patients with biochemically active medullary thyroid cancer.
    Medical condition: The disease we will be studying is medullary thyroid carcinoma. This type of thyroid carcinoma constitutes approximately 10% of all thyroid cancers. Treatment consists of a total thyroidectomy and ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005050-11 Sponsor Protocol Number: SeMMIviD Start Date*: 2019-03-08
    Sponsor Name:A.O. OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI
    Full Title: Effects of Selenium and cholecalciferol on hyperthyroidism due to Graves' disease treated with methimazole: a randomized, clinical, open label, pilot trial
    Medical condition: Graves' disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020850 Hyperthyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001006-41 Sponsor Protocol Number: ETHIC_pilot Start Date*: 2018-09-03
    Sponsor Name:Academisch Medisch Centrum
    Full Title: The Efficacy of TRH in Intensive Care patients; a dose finding study
    Medical condition: Non thyroidal illness syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000574-19 Sponsor Protocol Number: LT4RAIT Start Date*: 2014-03-24
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA
    Full Title: Experimental study for the evaluation of the effect of radioactive iodine therapy on free thyroxine circulating levels after oral administration of sodium levo-thyroxine in patients thyroidectomiz...
    Medical condition: patients thyroidectomized for differentiated thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004863 10057242 Post surgical hypothyroidism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001516-38 Sponsor Protocol Number: MISEM/2016 Start Date*: 2017-02-16
    Sponsor Name:PROF.EFISIO PUXEDDU, SEZIONE MEDICINA INTERNA SCIENZE ENDOCRINE E METABOLICHE, UNIVERSITà DI PERUGIA
    Full Title: Levothyroxine soft-gel efficacy with variation of intaking time in hypothyroidism replacement therapy
    Medical condition: patients who underwent total thyroidectomy followed or not by ablative radioiodine therapy for differentiated thyroid carcinoma and then treated with levothyroxine replacement therapy, in disease r...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10021114 Hypothyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000423-14 Sponsor Protocol Number: D1532C00065 Start Date*: 2013-05-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Diff...
    Medical condition: Differentiated Thyroid Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) IT (Completed) FR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001225-33 Sponsor Protocol Number: UC-0105/1401 Start Date*: 2014-07-21
    Sponsor Name:UNICANCER
    Full Title: Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations.
    Medical condition: Patient with BRAF V600 mutation determined on the primary and/or metastatic lesion in the following pathologies: . NSCLC . Ovarian cancer . Cholangiocarcinoma . Thyroid cancer . Prostatic canc...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019053 Hairy cell leukaemia PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071653 Gastrointestinal stromal cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000339-21 Sponsor Protocol Number: JK08.1.01 Start Date*: 2022-08-29
    Sponsor Name:Salubris Biotherapeutics, Inc.
    Full Title: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable ...
    Medical condition: Unresectable Locally Advanced or Metastatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085663 Clear cell papillary renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077840 Urothelial cancer of renal pelvis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040810 Skin carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014720 Endometrial adenocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083238 Luminal breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071114 Metastatic gastric adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005999-36 Sponsor Protocol Number: HZNP-TEP-402 Start Date*: 2022-05-24
    Sponsor Name:Horizon Therapeutics U.S.A., Inc.
    Full Title: A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durat...
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001369-28 Sponsor Protocol Number: 880 Start Date*: 2014-10-30
    Sponsor Name:Gateshead Health NHS Foundation Trust
    Full Title: THYRoxine in Acute Myocardial Infarction (ThyrAMI)
    Medical condition: Hypothyroidism and Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000676-42 Sponsor Protocol Number: PAP_RI1_2019/1 Start Date*: 2023-01-24
    Sponsor Name:University Center Hospital of Guadeloupe
    Full Title: Efficacy of metformin versus sitagliptin on benign thyroid nodules size in type 2 diabetes: a 2-years prospective multicentric study
    Medical condition: newly diagnosed subjects with uncomplicated T2DM and begnin TN of at least 2 cm of size, after pregnancy exclusion if women
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005732-28 Sponsor Protocol Number: LE-9999-401-BE Start Date*: 2013-06-14
    Sponsor Name:Takeda Belgium
    Full Title: A multicentre, open-label switch study to investigate the necessity of dose adjustment after switching from L-Thyroxine Christiaens® to the new levothyroxine sodium test formulation in (near) total...
    Medical condition: Patient that underwent a near total thyroidectomy and therefore are compelled to take levothyroxine hormone substition therapy.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10043777 Thyroidectomy total LLT
    16.0 10014698 - Endocrine disorders 10021114 Hypothyroidism PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 08:41:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA